cas 39065-95-7|| where to buy 4-(Chlorodifluoromethoxy)aniline

Produktname:4-(Chlorodifluoromethoxy)aniline

IUPAC Name:4-(chlorodifluoromethoxy)aniline

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM252669-1000g	in stock	ƃƿǑƥ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 39065-95-7 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:39065-95-7; Molekulare Formel:C7H6ClF2NO; Schmelzpunkt:-; SMILES-Code:NC1=CC=C(OC(F)(Cl)F)C=C1; Dichte:

: Katalognummer:CM252669; Molekulargewicht:193.58; Siedepunkt:231.9°C at 760 mmHg; Mdl-Nr.:MFCD01820809; Lagerung:Keep in dark place, store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Asciminib; Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile. Scemblix now approved for newly diagnosed and previously treated CML, allowing four times the patients access to potential new standard of care.
Scemblix is an orally available tyrosine kinase inhibitor that works by blocking the BCR-ABL1 fusion protein, a known hallmark of certain leukemias. The drug was first approved for CML three years ago, winning two indications. The first is for the treatment of Philadelphia chromosome-positive, chronic phase CML, for which the drug was given accelerated approval. The second is a full approval for the same patient population, with the additional specification that they carry the T315I mutation.